Cancer immunology research · 2025
Liver Metastases License Neutrophils through IL1 to Potentiate Cancer Progression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pearson Ashley N, Waninger Jessica, Huber Amanda K, Holcomb Erin A, James Jadyn G, Kyi Justine, Elaimy Ameer L, Wang Zhuwen, Lasse-Opsahl Emily L, SenGupta Shuvasree, Elliott David A, Choi Enid, Zhang Qiang, Morgan Meredith A, Chang Daniel T, Lawrence Theodore S, Courtney Adam, Shah Yatrik M, Knight Jason S, Pasca Di Magliano Marina, Yoo Shinjae, Crivelli Silvia, Parent Carole A, Ramnath Nithya, Bryant Alex K, Zou Weiping, Green Michael D
Аннотация
Liver metastases are associated with poor cancer outcomes in many solid malignancies, but the factors influencing the trajectory of patients with liver metastases are poorly defined. It is known that liver metastases suppress systemic antitumor immunity; however, the underlying mechanisms remain incompletely described. We report that liver metastases promote disease progression in patients and preclinical models. Patients with liver metastases progress rapidly, regardless of primary tumor type. In multiple murine models, we find that liver metastases potentiate neutrophil migration and activity. Neutrophils licensed by liver metastasis augment metastatic colonization in an IL1-dependent manner. Thus, liver metastasis rewires systemic immunity to promote cancer progression. This work has implications for treatment strategies to address the poor clinical outcomes associated with liver metastasis.